Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

Trial Profile

A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms SINGLE
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 08 Oct 2020 Results of pooled analysis assessing the efficacy and safety profile of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) relative to comparator ART in PLWH naive to ART by age group from four phase III/IIIb, presented at the 15th International Congress on Drug Therapy and HIV Infection
    • 30 Apr 2019 Results of post hoc analysis using VL data obtained from the timepoints shared by A5353, SPRING 1 and SINGLE trial published in the Journal of Antimicrobial Chemotherapy
    • 31 Oct 2018 Results comparing viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy using data from A5353, SPRING-1 and SINGLE (n=588) presented at the 14th International Congress on Drug Therapy and HIV Infection
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top